Global Restless Legs Syndrome Market Size study, by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), Treatment Type (Medication and Devices, Surgery), and Regional Forecasts 2022-2028

Global Restless Legs Syndrome Market Size study, by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), Treatment Type (Medication and Devices, Surgery), and Regional Forecasts 2022-2028

Global Restless Legs Syndrome Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 3.7% over the forecast period 2022-2028. Restless legs syndrome refers to the strong urge to move legs. Willis-Ekbom illness, often known as restless legs syndrome, is a neurological condition. As a result, Patients feel compelled to exercise their legs. The condition is sometimes regarded as a form of sleep disorder because it often manifests during sleep. When someone has restless legs syndrome, they frequently have an intense want to move their legs a lot, and because of this, their limbs begin to hurt. Women are shown to have a higher prevalence of restless legs syndrome than males. RLS can affect anybody at any age, however it is most frequently seen in middle-aged and older individuals. Rise in Prevalence of Restless Leg Syndrome and high Unmet Need of Treatment and Increasing Geriatric Population are the key factors driven the market growth in the coming years.
According to research released by Frontiers Media S.A. in March 2022, the reported prevalence of restless legs syndrome ranged between 3.9 percent and 14.3 percent, Moreover, 37.3 million Americans, or around 11.3 percent of the country's population, have diabetes, according to data from the Centers for Disease Control and Prevention released in 2022. However, side Effects Associated with Restless Syndrome Treatments impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Restless Legs Syndrome Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to rising prevalence of restless legs syndrome and rising affordability of drugs. However, Asia Pacific is expected to be the fastest growing region due to growing prevalence of neurological disorders and rising expenditure to develop healthcare infrastructure.

Major market players included in this report are:
Boehringer Ingelheim International GmbH
Arbor Pharmaceuticals, LLC
Psychocare Health Private Limited
Sun Pharmaceutical Industries Ltd
Viatris Inc
Restiffic
UCB S.A
Relegs
Glenmark Pharmaceutical
Noctrix Health, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Primary Restless Legs Syndrome
Secondary Restless Legs Syndrome
By Treatment Type:
Surgery
Medication and Devices
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Restless Legs Syndrome Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Boehringer Ingelheim International GmbH
Arbor Pharmaceuticals, LLC
Psychocare Health Private Limited
Sun Pharmaceutical Industries Ltd
Viatris Inc
Restiffic
UCB S.A
Relegs
Glenmark Pharmaceutical
Noctrix Health, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.